Pharming Group (PHAR)
(Delayed Data from NSDQ)
$10.96 USD
-0.15 (-1.35%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.08 +0.12 (1.09%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Pharming Group N.V. Sponsored ADR's dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
PHAR 10.96 -0.15(-1.35%)
Will PHAR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHAR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAR
New Strong Buy Stocks for August 1st
Best Momentum Stocks to Buy for July 25th
PHAR: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 25th
Best Momentum Stocks to Buy for July 17th
New Strong Buy Stocks for July 17th
Other News for PHAR
Pharming (PHAR) Stock Target Raised by Oppenheimer Following Q2 Results
Pharming price target raised by $1 at Oppenheimer, here's why
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Pharming Group N.V. 2025 Q2 - Results - Earnings Call Presentation
Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M